Literature DB >> 23948116

Angiographic assessment of myocardial perfusion in Tako-Tsubo syndrome.

Alberto R De Caterina1, Antonio Maria Leone, Leonarda Galiuto, Eloisa Basile, Elisa Fedele, Lazzaro Paraggio, Giovanni Luigi De Maria, Italo Porto, Giampaolo Niccoli, Francesco Burzotta, Carlo Trani, Antonio G Rebuzzi, Filippo Crea.   

Abstract

OBJECTIVES: To angiographically assess myocardial perfusion in patients with Tako-Tsubo syndrome (TTS) in comparison with control individuals and patients with ST-elevation myocardial infarction (STEMI).
BACKGROUND: Coronary microvascular dysfunction has been proposed as the pathophysiological mechanism underlying TTS.
METHODS: We retrospectively selected consecutive TTS patients showing typical left ventricular (LV) apical dysfunction admitted to our Department in the period 2007-2011 (n=25). We also enrolled an age and gender-matched control group showing normal coronary arteries (CTR, n=25), patients with STEMI undergoing primary percutaneous intervention with myocardial reperfusion (SR, n=25) or microvascular obstruction (SMVO, n=25). TIMI flow, TIMI frame count (TFC) and both qualitative and quantitative myocardial blush grade in LV apex were assessed. Specifically, myocardial perfusion was quantitatively evaluated using 'Quantitative Blush Evaluator' (QuBE), an open source software previously validated in the setting of STEMI.
RESULTS: In TTS, TIMI flow on the LAD was significantly lower and TFC significantly higher compared to CTR and SR (p=0.008 for both), while it did not significantly differ compared to SMVO (p=0.06). In TTS, MBG was significantly lower than that in CTR and SR (p=0.001 for both), while it was significantly higher than that in SMVO (p<0.001). In TTS, QuBE score was significantly lower than that in CTR and SR (p=0.001 for both) and higher than in SMVO (p=0.02).
CONCLUSIONS: Our data indicate that myocardial perfusion assessed during angiography is more impaired in patients with TTS than in patients with STEMI exhibiting myocardial reperfusion, while it is less impaired than in patients with STEMI exhibiting MVO.
© 2013.

Entities:  

Keywords:  Microvascular dysfunction; Myocardial blush grade; QuBE; Tako-Tsubo syndrome

Mesh:

Year:  2013        PMID: 23948116     DOI: 10.1016/j.ijcard.2013.07.172

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

Review 1.  Coronary microvascular dysfunction in Takotsubo syndrome: cause or consequence.

Authors:  Shams Y-Hassan
Journal:  Am J Cardiovasc Dis       Date:  2021-04-15

Review 2.  Stress Cardiomyopathy Diagnosis and Treatment: JACC State-of-the-Art Review.

Authors:  Horacio Medina de Chazal; Marco Giuseppe Del Buono; Lori Keyser-Marcus; Liangsuo Ma; F Gerard Moeller; Daniel Berrocal; Antonio Abbate
Journal:  J Am Coll Cardiol       Date:  2018-10-16       Impact factor: 24.094

3.  Anabolic androgenic steroid-induced Takotsubo cardiomyopathy.

Authors:  Angelo Placci; Gianluigi Sella; Giancarlo Bellanti; Massimo Margheri
Journal:  BMJ Case Rep       Date:  2015-03-24

4.  Characteristics of coronary microcirculatory function in patients with Takotsubo syndrome.

Authors:  Giuseppina Novo; Angelo Quagliana; Dario Buccheri; Salvatore Rizzo; Salvatore Giambanco; Francesco Giambanco; Salvatore Evola; Giovanna Geraci; Salvatore Novo
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 5.  Coronary blood flow in heart failure: cause, consequence and bystander.

Authors:  Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2022-01-13       Impact factor: 12.416

6.  Takotsubo Cardiomyopathy: One More Angiographic Evidence of Microvascular Dysfunction.

Authors:  Marco Loffi; Andrea Santangelo; Martin Kozel; Viktor Kocka; Tomas Budesinsky; Libor Lisa; Petr Tousek
Journal:  Biomed Res Int       Date:  2018-03-14       Impact factor: 3.411

Review 7.  An Emerging Cardiovascular Disease: Takotsubo Syndrome.

Authors:  Sara Moscatelli; Fabrizio Montecucco; Federico Carbone; Alberto Valbusa; Laura Massobrio; Italo Porto; Claudio Brunelli; Gian Marco Rosa
Journal:  Biomed Res Int       Date:  2019-10-30       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.